Pharmaceutical Business News

Celgene Partners with Prothena Therapeutics in Potential $2B Deal

(BioSpace) Shares of Prothena Corporation plc have shot up more than 18 percent in premarket trading this morning after the company forged a collaboration with pharma giant Celgene to develop new therapies for a broad range of neurodegenerative diseases, including Alzheimer’s and ALS. Celgene will pay Prothena $150 million in upfront money with the promise of future regulatory and commercial milestone payments. According to a filing with the U.S. Securities
Alzheimers and Dementia

New Player in Alzheimer’s Disease Pathogenesis Identified

Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check. The study, published in Nature Communications, shows that membralin regulates the cell’s machinery for producing beta-amyloid (or amyloid beta, Aβ), the protein that causes neurons to die in Alzheimer’s disease. “Our results suggest a new path toward future treatments for Alzheimer’s disease,” says Huaxi Xu, Ph.D., the
Biotechnology Clinical Trials

Pre-Clinical Study Suggests Parkinson’s Could Start in Gut Endocrine Cells

Recent research on Parkinson’s disease has focused on the gut-brain connection, examining patients’ gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating disease. But scientists understand little about what’s happening in the gut -- the ingestion of environmental toxins or germs, perhaps -- that leads to brain damage and the hallmarks of Parkinson’s such as tremors, stiffness and
Alzheimers and Dementia

Diagnostic biomarkers in saliva show promise in recognizing early Alzheimer’s disease

Your spit may hold a clue to future brain health. Investigators at the Beaumont Research Institute, part of Beaumont Health in Michigan, are hopeful that their study involving small molecules in saliva will help identify those at risk of developing Alzheimer's disease - a neurologic condition predicted to reach epidemic proportions worldwide by 2050. Their study, "Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics" was
Alzheimers and Dementia

Researchers Identify How Inflammation Spreads Through the Brain After Injury

Findings Could Transform How Understanding of Brain Injury and Disease Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases. The findings were published today in a study in the Journal of Neuroinflammation. This new understanding has the potential to
Alzheimers and Dementia

Estrogen Patch in Newly Postmenopausal Women May Reduce Alzheimer’s Risk

Can estrogen preserve brain function and decrease the risk of Alzheimer’s disease when given early in menopause? Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer’s disease, a Mayo Clinic study published this month in the Journal of Alzheimer’s Disease found. Ultimately, these deposits harm neurons, leading to cognitive problems. In the study, women
Alzheimers and Dementia

Penn Medicine Team and Collaborators Receive NIH Award to Launch Genomics Center on Alzheimer’s Disease

A five-year, projected $10.8 million award from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), will establish the Coordinating Center for Genetics and Genomics of Alzheimer’s Disease, a joint venture of researchers from the Perelman School of Medicine at the University of Pennsylvania and five other institutions. Penn will receive an estimated $4.5 million from the grant. The Center is led by Gerard D.
Alzheimers and Dementia

The Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Degeneration

As of 2016, we still don’t have a single approved drug to cure or even slow the progression of diseases caused by damage to the brain’s neurons. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) are determined to change that. Today, they announce a $10 million investment to develop effective treatments for frontotemporal degeneration (FTD), a complex form of dementia that affects more than 50,000